Annovis Advances Buntanetap in Alzheimer’s Phase 3
Malvern, Pennsylvania — August 14, 2026 Annovis Bio, Inc. announced that its pivotal Phase 3 Alzheimer’s disease trial of...
Parkinson’s Disease
Advertisement
Definium Therapeutics Reports Positive Phase 3 GAD Results
NEW YORK, August 12, 2026 Definium Therapeutics, Inc. announced positive topline results from the Phase 3 Voyage study evaluating...
Alterity Expands ATH434 Potential in Neurodegenerative Disease
MELBOURNE, Australia and SAN FRANCISCO, USA, August 12, 2026 Alterity Therapeutics Limited announced that the U.S. Patent and Trademark...
AC Immune Receives FDA Fast Track Designation for ACI-7104 in Parkinson’s
LAUSANNE, Switzerland, August 11, 2026 AC Immune SA announced that the U.S. Food and Drug Administration (FDA) has granted...
BioVie Advances Parkinson’s Program with Phase 2 Success
CARSON CITY, Nev., August 6, 2026 BioVie Inc. announced positive topline results from its Phase 2 SUNRISE-PD trial, demonstrating...
Advertisements
Lunai Bioworks Expands Parkinson’s AI Drug Discovery Alliance
Sacramento & San Diego, California, August 4, 2026 Lunai Bioworks Inc. has announced a definitive Master Collaboration Agreement with...
CND Life Sciences Secures Growth Funding for Syn-One Test
Scottsdale, Arizona & Boca Raton, Florida, August 4, 2026 CND Life Sciences has announced the successful completion of a...
Dasher Neuroscience Advances YA-101 Phase 2 Trial
TAIPEI, July 28, 2026 Dasher Neuroscience Holdings Inc. has successfully completed patient enrollment in its global Phase 2 clinical...
Galmed Advances Brain-Targeted Aramchol for Parkinson’s
Ramat-Gan, Israel, July 28, 2026 Galmed Pharmaceuticals Ltd. has announced a significant advancement in the development of Aramchol orally...
Serina Therapeutics Completes First Cohort in SER-252 Phase 1 Trial
Serina Therapeutics, Huntsville, Ala., July 23, 2026 Serina Therapeutics announced the successful completion of enrollment and dosing in Cohort...
Advertisement
